If nothing else -- and if they can't for some reason discuss what happened to the IPO -- they need to update shareholders on the Pitt-Hopkins clinical trial, in a clear and concise way. Has it even started? Nobody knows. There were milestones for Q1 -- and we're now half way through Q2.
We are shareholders. We have rights. Do they really think we're going to tolerate yet another year of dead silence? Dr. Musick, I'm a reasonable guy. But this can't go on much longer. If the IPO is dead, use your influence to follow up on your original promise to relist on an OTC exchange, without a reverse split. Either that or make an offer to buy back the previously public shares.
You can't sequester our capital forever. There are damages involved, and they are growing by the day. It's March 2023. The five year plan from 2018 is over. The Company is public again, in every respect except the one that matters to shareholders. Tell us what is going on, and when we will be liquid again, or this just isn't going to end well for anyone.
